Shattuck Labs, Inc. Comprehensive Income
Shattuck Labs, Inc. (STTK) reported Comprehensive Income of -$15.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-11
- Shattuck Labs, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$15.21M.
- Shattuck Labs, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$14.77M.
- Shattuck Labs, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$12.59M.
- Shattuck Labs, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$10.05M.
- Shattuck Labs, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$48.80M.
- Shattuck Labs, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$75.41M.
- Shattuck Labs, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$86.42M.
- Shattuck Labs, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$102.26M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.21M 10-Q · filed 2026-08-11 | -$29.99M 10-Q · filed 2026-08-11 | -$42.58M derived: sum of 3 quarters · filed 2026-08-11 | -$52.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$14.77M 10-Q · filed 2026-05-07 | -$27.36M derived: sum of 2 quarters · filed 2026-05-07 | -$37.42M derived: sum of 3 quarters · filed 2026-05-07 | -$49.87M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$12.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$22.64M derived: sum of 2 quarters · filed 2026-03-05 | -$35.10M derived: sum of 3 quarters · filed 2026-08-11 | -$48.80M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$10.05M 10-Q · filed 2025-11-06 | -$22.51M derived: sum of 2 quarters · filed 2026-08-11 | -$36.22M 10-Q · filed 2025-11-06 | -$54.94M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$12.46M 10-Q · filed 2026-08-11 | -$26.16M 10-Q · filed 2026-08-11 | -$44.89M derived: sum of 3 quarters · filed 2026-08-11 | -$61.51M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$13.70M 10-Q · filed 2026-05-07 | -$32.43M derived: sum of 2 quarters · filed 2026-05-07 | -$49.05M derived: sum of 3 quarters · filed 2026-05-07 | -$70.59M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$18.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$35.35M derived: sum of 2 quarters · filed 2026-03-05 | -$56.89M derived: sum of 3 quarters · filed 2026-03-05 | -$75.41M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$16.62M 10-Q · filed 2025-11-06 | -$38.16M derived: sum of 2 quarters · filed 2025-11-06 | -$56.68M 10-Q · filed 2025-11-06 | -$74.37M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$21.54M 10-Q · filed 2025-08-14 | -$40.06M 10-Q · filed 2025-08-14 | -$57.76M derived: sum of 3 quarters · filed 2025-08-14 | -$85.22M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$18.52M 10-Q · filed 2025-05-01 | -$36.21M derived: sum of 2 quarters · filed 2025-05-01 | -$63.67M derived: sum of 3 quarters · filed 2025-05-01 | -$84.75M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | -$17.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$45.15M derived: sum of 2 quarters · filed 2025-03-27 | -$66.23M derived: sum of 3 quarters · filed 2025-03-27 | -$86.42M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$27.46M 10-Q · filed 2024-11-14 | -$48.54M derived: sum of 2 quarters · filed 2024-11-14 | -$68.73M 10-Q · filed 2024-11-14 | -$93.68M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$21.08M 10-Q · filed 2024-08-01 | -$41.27M 10-Q · filed 2024-08-01 | -$66.22M derived: sum of 3 quarters · filed 2024-08-01 | -$91.08M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$20.19M 10-Q · filed 2024-05-02 | -$45.14M derived: sum of 2 quarters · filed 2024-05-02 | -$70.00M derived: sum of 3 quarters · filed 2024-05-02 | -$97.95M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$24.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$49.81M derived: sum of 2 quarters · filed 2024-02-29 | -$77.77M derived: sum of 3 quarters · filed 2024-02-29 | -$102.26M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$24.86M 10-Q · filed 2023-11-09 | -$52.81M derived: sum of 2 quarters · filed 2023-11-09 | -$77.31M 10-Q · filed 2023-11-09 | -$68.19M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$27.95M 10-Q · filed 2023-08-10 | -$52.45M 10-Q · filed 2023-08-10 | -$43.33M derived: sum of 3 quarters · filed 2023-08-10 | -$60.95M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$24.50M 10-Q · filed 2023-05-09 | -$15.38M derived: sum of 2 quarters · filed 2023-05-09 | -$33.00M derived: sum of 3 quarters · filed 2023-05-09 | -$57.56M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $9.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$8.50M derived: sum of 2 quarters · filed 2023-02-23 | -$33.06M derived: sum of 3 quarters · filed 2023-02-23 | -$45.47M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$17.62M 10-Q · filed 2022-11-09 | -$42.17M derived: sum of 2 quarters · filed 2022-11-09 | -$54.59M 10-Q · filed 2022-11-09 | -$66.65M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$24.56M 10-Q · filed 2022-08-11 | -$36.97M 10-Q · filed 2022-08-11 | -$49.03M derived: sum of 3 quarters · filed 2022-08-11 | -$60.89M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$12.41M 10-Q · filed 2022-05-12 | -$24.48M derived: sum of 2 quarters · filed 2022-05-12 | -$36.33M derived: sum of 3 quarters · filed 2022-05-12 | -$42.64M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$12.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$23.92M derived: sum of 2 quarters · filed 2022-03-15 | -$30.23M derived: sum of 3 quarters · filed 2022-03-15 | -$36.72M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$11.86M 10-Q · filed 2021-11-09 | -$18.16M derived: sum of 2 quarters · filed 2021-11-09 | -$24.66M 10-Q · filed 2021-11-09 | -$32.09M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$6.30M 10-Q · filed 2021-08-12 | -$12.80M 10-Q · filed 2021-08-12 | -$20.23M derived: sum of 3 quarters · filed 2021-08-12 | -$27.50M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$6.49M 10-Q · filed 2021-05-10 | -$13.93M derived: sum of 2 quarters · filed 2021-05-10 | -$21.20M derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | -$7.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$14.70M derived: sum of 2 quarters · filed 2021-03-16 | -$23.93M 10-K · filed 2021-03-16 | |
| 2019-09-30 | -$7.27M 10-Q · filed 2020-11-13 | -$16.49M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |